Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 29, 2025Cancer Research

Abstract A089: Improving Therapeutic Window of Claudin 18.2-Targeted CAR-T cells in Pancreatic Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

ECElizabeth J. CarstensKTKazuki TakahashiMVMartina De Vizio

Discussion

Loading...

Member takes

Overview

Novel CAR-T cells targeting claudin 18.2 showed improved efficacy and reduced toxicities in pancreatic cancer, indicating a better therapeutic window.

Key Points

  • 5795-VH based CAR-T cells demonstrated long-term tumor control with minimal toxicity, while 5797-VH and CT041 had significant adverse effects.
  • The average overall survival for CT041 treated groups was 31-36 days, while the 5795-VH groups did not reach median overall survival by 60 days.
  • High affinity binders were evaluated using SPR, with 5795-IgG showing a significantly lower affinity compared to CT041-IgG and 5797-IgG.
  • Engineering a CAR with optimal therapeutic window requires careful analysis of anticipated toxicity and binding kinetics.

Cite This Study

Carstens et al. (2025) studied this question.

synapsesocial.com/papers/68da58d8c1728099cfd10f20https://doi.org/10.1158/1538-7445.pancreatic25-a089
View Full Paper
Ask AI
Bookmark
Share